Stereotactic radiation extends long-term survival
Stereotactic radiation extends long-term survival for some patients with stage...Read more on AuntMinnie.comRelated Reading: ASTRO: SABR is effective for oligometastatic cancers ASTRO: Weekly breast radiation therapy is safe ASTRO: AI's rad therapy future is in predicting outcomes Is radiation therapy warranted for DCIS postlumpectomy? ASTRO: Short radiation course safe for breast cancer
AbstractPurposeIt has been accepted that radiation therapy (RT) for ductal carcinoma in situ (DCIS) has no survival benefit despite increasing local control. However, a recent large database study reported a small but significant benefit. Using a Korean population-based large database, we examined the survival benefit of RT for DCIS after breast-conserving surgery (BCS) and analyzed which subgroup might derive benefit from it.MethodsData from 6038 female DCIS patients who underwent BCS with or without RT between 1993 and 2012 were included in this study. We used propensity score analysis to control for differences in basel...
Conditions: Invasive Ductal Breast Carcinoma; Invasive Ductal Carcinoma, Breast; DCIS; DCIS Grade 1; DCIS Grade 2; Breast Cancer Intervention: Radiation: Accelerated Partial Breast Irradiation Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
ConclusionsWith mature follow-up, our rates of local recurrence following breast-conserving therapy for DCIS remain very low (1.5% at 10 years). The incidence of CBC was higher than the LR incidence. Predisposing factors for the development of CBC are worthy of investigation.
Breast conserving surgery (BCS) followed by radiation therapy (RT) is the primary management for many women with early-stage, invasive breast cancer and ductal carcinoma in situ (DCIS) [1 –4]. Most women achieve good to excellent cosmesis after BCS and RT but some experience cosmetic failure, defined as fair or poor cosmetic outcomes [5–17]. However, comparisons of cosmetic outcomes across international jurisdictions using contemporary surgical and RT techniques for DCIS are lack ing.
CONCLUSIONS: Among the patients with invasive carcinoma or DCIS within less than 1 mm from the resection margin, adjuvant RT with higher dose > 66Gy EQD2 might improve local control. Further prospective studies are warranted to validate the benefit and risk of a high dose boost after BCS in patients with a positive resection margin. PMID: 31265973 [PubMed - as supplied by publisher]
ConclusionPLM plays an important role in the evaluation of patients undergoing breast conservation for breast cancer presenting with microcalcifications. Residual malignancy was detected on positive PLM in 6% of patients with negative margins.
Approximately 60,000 women in the United States are diagnosed with ductal carcinoma in situ (DCIS) annually.1 Although DCIS is both a precursor and risk factor for development of invasive breast cancer (IBC), survival after treatment of DCIS is very high regardless of treatment approach.2 After lumpectomy, radiation therapy (RT) decreases local recurrence rates by 50% relatively but has no apparent impact on distant metastases or survival.2 Breast preservation and prevention of local recurrence, either in the form of DCIS or invasive cancer, is thus the primary oncologic benefit of RT in patients who received a diagnosis of DCIS.
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. âUnfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,â said Lori Chmura, CEO of Dune Medical Devices. âThe doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and theyâre t...
ConclusionThe HF schedule with CB in DCIS patients is well tolerated and associated with excellent clinical outcomes. This schedule affords the benefit of delivering higher dose to the lumpectomy site without protracting overall treatment time.